Journal Article
. 2019 Oct;5().
doi: 10.1038/s41523-019-0129-3.

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia

Lindsay J Collin 1 Ming Yan 1 Renjian Jiang 1 Kevin C Ward 1 Brittany Crawford 2 Mylin A Torres 3 Keerthi Gogineni 3 Preeti D Subhedar 3 Samantha Puvanesarajah 4 Mia M Gaudet 4 Lauren E McCullough 1 
Affiliations
  • PMID: 31583272
  •     46 References
  •     4 citations

Abstract

Among women diagnosed with stage I-IIIa, node-negative, hormone receptor (HR)-positive breast cancer (BC), Oncotype DX recurrence scores (ODX RS) inform chemotherapy treatment decisions. Differences in recurrence scores or testing may contribute to racial disparities in BC mortality among women with HR+ tumors. We identified 12,081 non-Hispanic White (NHW) and non-Hispanic Black (NHB) BC patients in Georgia (2010-2014), eligible to receive an ODX RS. Logistic regression was used to estimate the odds of chemotherapy receipt by race and ODX RS. Cox proportional hazard regression was used to calculate the hazard ratios (HRs) comparing BC mortality rates by race and recurrence score. Receipt of Oncotype testing was consistent between NHB and NHW women. Receipt of chemotherapy was generally comparable within strata of ODX RS-although NHB women with low scores were slightly more likely to receive chemotherapy (OR = 1.16, 95% CI 0.77, 1.75), and NHB women with high scores less likely to receive chemotherapy (OR = 0.77, 95% CI 0.48, 1.24), than NHW counterparts. NHB women with a low recurrence score had the largest hazard of BC mortality (HR = 2.47 95% CI 1.22, 4.99) compared to NHW women. Our data suggest that additional tumor heterogeneity, or other downstream treatment factors, not captured by ODX, may be drivers of racial disparities in HR+ BC.

Keywords: Predictive markers; Prognostic markers.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change.
Bobby Daly, Olufunmilayo I Olopade.
CA Cancer J Clin, 2015 May 12; 65(3). PMID: 25960198
Highly Cited. Review.
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries.
Wenjie Zhu, Edith A Perez, +2 authors, Binghe Xu.
PLoS One, 2015 May 29; 10(5). PMID: 26020519    Free PMC article.
Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.
E J Blok, E Bastiaannet, +4 authors, C J H van de Velde.
Cancer Treat Rev, 2017 Nov 28; 62. PMID: 29175678
Systematic Review.
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial.
Stephen R Cole, Elizabeth A Stuart.
Am J Epidemiol, 2010 Jun 16; 172(1). PMID: 20547574    Free PMC article.
Highly Cited.
Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.
Li Tao, Scarlett Lin Gomez, +2 authors, Christina A Clarke.
Cancer Epidemiol Biomarkers Prev, 2015 May 15; 24(7). PMID: 25969506    Free PMC article.
Long term side effects of adjuvant chemotherapy in patients with early breast cancer.
Jessica J Tao, Kala Visvanathan, Antonio C Wolff.
Breast, 2015 Aug 25; 24 Suppl 2. PMID: 26299406    Free PMC article.
Review.
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
Betsy A Kohler, Recinda L Sherman, +11 authors, Lynne Penberthy.
J Natl Cancer Inst, 2015 Apr 01; 107(6). PMID: 25825511    Free PMC article.
Highly Cited.
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.
Dawn L Hershman, Theresa Shao, +6 authors, Alfred I Neugut.
Breast Cancer Res Treat, 2010 Aug 31; 126(2). PMID: 20803066    Free PMC article.
Highly Cited.
"Toward a clearer definition of confounding" revisited with directed acyclic graphs.
Penelope P Howards, Enrique F Schisterman, +2 authors, Clarice R Weinberg.
Am J Epidemiol, 2012 Aug 21; 176(6). PMID: 22904203    Free PMC article.
Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.
Carol E DeSantis, Rebecca L Siegel, +4 authors, Ahmedin Jemal.
CA Cancer J Clin, 2016 Feb 26; 66(4). PMID: 26910411
Highly Cited.
Comparison of SEER Treatment Data With Medicare Claims.
Anne-Michelle Noone, Jennifer L Lund, +4 authors, Joan L Warren.
Med Care, 2014 Mar 19; 54(9). PMID: 24638121    Free PMC article.
Highly Cited.
Gene expression profiling in breast cancer: classification, prognostication, and prediction.
Jorge S Reis-Filho, Lajos Pusztai.
Lancet, 2011 Nov 22; 378(9805). PMID: 22098854
Highly Cited. Review.
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.
Scott D Ramsey, William E Barlow, +6 authors, Gabriel N Hortobagyi.
Contemp Clin Trials, 2012 Sep 25; 34(1). PMID: 23000081    Free PMC article.
Review.
ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
MiHee M Park, Joshua J Ebel, Weiquiang Zhao, Debra L Zynger.
Breast J, 2013 Nov 23; 20(1). PMID: 24261318
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
David J Press, Abiola Ibraheem, +3 authors, Dezheng Huo.
Breast Cancer Res Treat, 2017 Nov 29; 168(1). PMID: 29181717
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Disparities in breast cancer characteristics and outcomes by race/ethnicity.
Siew Loon Ooi, Maria Elena Martinez, Christopher I Li.
Breast Cancer Res Treat, 2010 Nov 16; 127(3). PMID: 21076864    Free PMC article.
Highly Cited.
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Erica T Warner, Rulla M Tamimi, +9 authors, Ann H Partridge.
J Clin Oncol, 2015 May 13; 33(20). PMID: 25964252    Free PMC article.
Highly Cited.
Transportability of Trial Results Using Inverse Odds of Sampling Weights.
Daniel Westreich, Jessie K Edwards, +2 authors, Stephen R Cole.
Am J Epidemiol, 2017 May 24; 186(8). PMID: 28535275    Free PMC article.
Highly Cited.
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
Patients' perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey.
Domenica Lorusso, Emilio Bria, +3 authors, Annamaria Mancuso.
Eur J Cancer Care (Engl), 2016 Dec 23; 26(2). PMID: 28004440
Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Cameron Neely, Shuo You, +3 authors, Xiaoxian Li.
Breast J, 2018 Sep 20; 24(6). PMID: 30230095
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.
Jean G Ford, Mollie W Howerton, +9 authors, Eric B Bass.
Cancer, 2007 Nov 17; 112(2). PMID: 18008363
Highly Cited. Systematic Review.
Generalizing Study Results: A Potential Outcomes Perspective.
Catherine R Lesko, Ashley L Buchanan, +3 authors, Stephen R Cole.
Epidemiology, 2017 Mar 28; 28(4). PMID: 28346267    Free PMC article.
Highly Cited. Review.
Generalizability of randomized trial results to target populations: Design and analysis possibilities.
Elizabeth A Stuart, Benjamin Ackerman, Daniel Westreich.
Res Soc Work Pract, 2018 Jul 24; 28(5). PMID: 30034203    Free PMC article.
Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Stephanie B Wheeler, Jennifer Spencer, +8 authors, Katherine E Reeder-Hayes.
J Natl Cancer Inst, 2018 Sep 22; 111(5). PMID: 30239824    Free PMC article.
Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
Javaid Iqbal, Ophira Ginsburg, +2 authors, Steven A Narod.
JAMA, 2015 Jan 15; 313(2). PMID: 25585328
Highly Cited.
Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.
Megan C Roberts, Stephanie B Wheeler, Katherine Reeder-Hayes.
Am J Public Health, 2015 Apr 24; 105 Suppl 3. PMID: 25905855    Free PMC article.
Systematic Review.
Recommendations for presenting analyses of effect modification and interaction.
Mirjam J Knol, Tyler J VanderWeele.
Int J Epidemiol, 2012 Jan 19; 41(2). PMID: 22253321    Free PMC article.
Highly Cited.
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
William J Gradishar, Benjamin O Anderson, +30 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2017 Apr 14; 15(4). PMID: 28404755
Highly Cited.
Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Vivek H Murthy, Harlan M Krumholz, Cary P Gross.
JAMA, 2004 Jun 10; 291(22). PMID: 15187053
Highly Cited.
21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Mary Jo Lund, Marina Mosunjac, +7 authors, Ruth M O'Regan.
Cancer, 2011 Jul 02; 118(3). PMID: 21720988
Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
Tanya Keenan, Beverly Moy, +6 authors, Aditya Bardia.
J Clin Oncol, 2015 Sep 16; 33(31). PMID: 26371147    Free PMC article.
Highly Cited.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L Potosky, Suzanne C O'Neill, +8 authors, Marc D Schwartz.
Cancer, 2015 Aug 21; 121(22). PMID: 26291519    Free PMC article.
Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Brigette A Davis, Jenerius A Aminawung, +5 authors, Cary P Gross.
J Natl Compr Canc Netw, 2017 Mar 10; 15(3). PMID: 28275035
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.
Lisa A Newman, Kent A Griffith, +3 authors, Graham A Colditz.
J Clin Oncol, 2006 Mar 22; 24(9). PMID: 16549828
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
Breast cancer deaths averted over 3 decades.
R Edward Hendrick, Jay A Baker, Mark A Helvie.
Cancer, 2019 Feb 12; 125(9). PMID: 30740647
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Megan C Roberts, Dave P Miller, Steven Shak, Valentina I Petkov.
Breast Cancer Res Treat, 2017 Mar 01; 163(2). PMID: 28243896
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Kent F Hoskins, Oana C Danciu, Naomi Y Ko, Gregory S Calip.
JAMA Oncol, 2021 Jan 22; 7(3). PMID: 33475714    Free PMC article.
Neighborhood-Level Redlining and Lending Bias Are Associated with Breast Cancer Mortality in a Large and Diverse Metropolitan Area.
Lindsay J Collin, Anne H Gaglioti, +7 authors, Lauren E McCullough.
Cancer Epidemiol Biomarkers Prev, 2020 Oct 04; 30(1). PMID: 33008873    Free PMC article.
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.
Della Makower, Juan Lin, Xiaonan Xue, Joseph A Sparano.
NPJ Breast Cancer, 2021 Mar 03; 7(1). PMID: 33649322    Free PMC article.